Biochemistry majors Tristan Mistkawi and Alex Egdell are among nine UO undergraduate researchers awarded minigrants through the Undergraduate Research Opportunity Program (UROP), a unit within the Office of the Vice President for Research and Innovation. The $1000 awards are given to students to assist with research expenses including purchasing supplies and materials and paying for travel that is necessary to conduct research.
Tristan is conducting research in the Haley lab on electronic properties of indenofluorenes and their derivatives, and Alex is in the Jasti lab doing reasearch focused on the synthesis of alkyne substituted cycloparaphenylenes for conjugated polymers. Both scholars will present their research at the UO Undergraduate Research Symposium on May 17, 2018.
One of the most widely used drugs to fight cancer could become more effective and safer, based on findings emerging from the lab of UO chemist Vickie DeRose.
In two recently published papers, separate projects using different approaches and led by two of DeRose’s doctoral students have made new predictions for where the platinum-carrying drug cisplatin binds in cells.
Read more about the DeRose Lab’s research and its implications for cancer treatment in AroundtheO
Read more about Prof. Hendon and his research in AroundtheO’s article: Dr. Coffee
Using computer simulations, UO Biochemist Mike Harms and graduate researcher Zach Sailer thought that they could manipulate a protein one mutation at a time and predict its evolution. They failed, but the team harvested information that may be useful for understanding problems such as antibiotic resistance.
Read the full article in AroundtheO
A discovery in Marina Guenza‘s UO chemistry lab that was recently published in a major physics journal, Physical Review Letters, is already being tapped by outside scientists working on a new medical treatment for tuberculosis.
Read the paper:
Physical Review Letters : Universality and Specificity in Protein Fluctuation Dynamics
Read more about the lab’s discovery:
A new anti-inflammatory drug moving into phase two clinical trials to treat two serious diseases was built on a scientific collaboration with UO chemist, Bruce Branchaud.
Read more in AroundtheO and the Daily Emerald: